SA PRO
Free Account
ADC Therapeutics S.A.ADCTNYSE
LOADING
|||
OverviewChartsNewsFundamentalsEarningsAnalysts

Analyst Sentiment

Analysts lean bullish — 58% recommend buying.

Consensus Rating
Buy
12 analysts·Moderate coverage
58%
Rating Distribution
Strong Buy
00%
Buy
758%
Hold
433%
Sell
18%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Analysts see significant upside — consensus target 92% higher.

Bear Case
$5.00
+28%
Consensus
$7.50
+92%
Bull Case
$10.00
+156%
Price Range12 analysts
Low
Consensus
High
$5.00
$10.00
Current Target
Current Price
$3.90
Upside to Target
$3.60

Price targets are 12-month forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Earnings Surprises

Recent Analyst Actions

Dec 3, 2025RBC Capital
RBC Capital on ADC Therapeutics (ADCT): 'We think the downside is unwarranted and would be buyers on weakness'
Target:$5.00
+26.4%from $3.96
Nov 12, 2025Guggenheim
Guggenheim Reiterates Buy Rating on ADC Therapeutics (ADCT)
Target:$10.00
+151.9%from $3.97
May 7, 2024H.C. Wainwright
ADC Therapeutics (ADCT) PT Lowered to $8 at H.C. Wainwright
Target:$8.00
+79.8%from $4.45
Mar 13, 2024Jefferies
ADC Therapeutics (ADCT) PT Lowered to $13 at Jefferies
Target:$13.00
+233.3%from $3.90
Nov 14, 2022Morgan Stanley
Morgan Stanley Maintains Equal-Weight on ADC Therapeutics, Lowers Price Target to $7
Target:$7.00
+70.7%from $4.10
Sep 9, 2022Morgan Stanley
ADC Therapeutics downgraded to Equal Weight from Overweight at Morgan Stanley
Target:$11.00
+68.7%from $6.52
Aug 22, 2022H.C. Wainwright
HC Wainwright & Co. Maintains Buy on ADC Therapeutics, Lowers Price Target to $20
Target:$20.00
+137.5%from $8.42

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance